HUP0400204A2 - A Leishmania parazita virulenciájával kapcsolatos gének - Google Patents

A Leishmania parazita virulenciájával kapcsolatos gének

Info

Publication number
HUP0400204A2
HUP0400204A2 HU0400204A HUP0400204A HUP0400204A2 HU P0400204 A2 HUP0400204 A2 HU P0400204A2 HU 0400204 A HU0400204 A HU 0400204A HU P0400204 A HUP0400204 A HU P0400204A HU P0400204 A2 HUP0400204 A2 HU P0400204A2
Authority
HU
Hungary
Prior art keywords
protein
proteins
cys
lmpdi
leishmaniasis
Prior art date
Application number
HU0400204A
Other languages
English (en)
Inventor
Yosser Ben Achour
Mehdi Chenik
Hechmi Louzir
Koussay Dellagi
Original Assignee
Institut Pasteur De Tunis
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur De Tunis, Institut Pasteur filed Critical Institut Pasteur De Tunis
Publication of HUP0400204A2 publication Critical patent/HUP0400204A2/hu
Publication of HUP0400204A3 publication Critical patent/HUP0400204A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány a leishmaniasis elleni küzdelemmel foglalkozik. Atalálmány tárgyát a Leishmania major szabadföldi izolátumáhólazonosított gén által kódolt, fehérjediszulfid-izomeráz (PI)I)potenciális aktív helyének szekvenciájával (Cys-Gly-His-Cys) megegyezőkét régiót hordozó, LmPDI-nek nevezett fehérje képezi. Ezen LmPDIfehérje főként a parazita leginkább fertőző izolátumaibanexpresszálódik. E fehérje elsősorban új terápiás célpont lehet aleishmaniasis elleni hatóanyagok kifejlesztésében, vagy alkalmazhatjukemberi vagy állati gazdák leishmaniasis elleni védelmére szolgálóvakcinakészítményekben. A találmány tárgyát képezik továbbá a fehérjéttartalmazó fúziós fehérjék, a fehérjéket kódoló nukleinsavak, azttartalmazó vektorok és sejtek, a fehérjék ellen termeltetettantitestek, illetve a fentieket tartalmazó immunogén és gyógyászatikészítmények. A találmány tárgyát képezik továbbá eljárások Leishmaniamajor szaporodását gátló molekulák szkrínelésére. Ó
HU0400204A 2001-06-18 2002-06-17 Gene associated with leishmania parasite virulence HUP0400204A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107985A FR2826018B1 (fr) 2001-06-18 2001-06-18 Gene associe a la virulence du parasite leishmania
PCT/FR2002/002086 WO2002103002A2 (fr) 2001-06-18 2002-06-17 Gene associe a la virulence du parasite leishmania

Publications (2)

Publication Number Publication Date
HUP0400204A2 true HUP0400204A2 (hu) 2005-04-28
HUP0400204A3 HUP0400204A3 (en) 2010-01-28

Family

ID=8864458

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400204A HUP0400204A3 (en) 2001-06-18 2002-06-17 Gene associated with leishmania parasite virulence

Country Status (16)

Country Link
EP (1) EP1414967B1 (hu)
JP (2) JP2004537299A (hu)
KR (1) KR20040023621A (hu)
CN (2) CN101274960A (hu)
AU (2) AU2002345672B2 (hu)
BR (1) BR0210486A (hu)
CZ (1) CZ20033430A3 (hu)
FR (1) FR2826018B1 (hu)
HR (1) HRP20031046A2 (hu)
HU (1) HUP0400204A3 (hu)
MX (1) MXPA03011904A (hu)
NZ (1) NZ530459A (hu)
PL (1) PL367113A1 (hu)
WO (1) WO2002103002A2 (hu)
YU (1) YU99603A (hu)
ZA (1) ZA200309739B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540736A1 (en) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
CA2604640A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
EP2141248B1 (en) * 2008-07-03 2012-12-12 Institut Pasteur Methods to identify leishmania virulence factors
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
WO2012062861A1 (en) * 2010-11-10 2012-05-18 Laboratorios Leti, S.L. New adjuvant
CN106085995B (zh) * 2016-06-15 2019-07-12 华南理工大学 一种基因定点改造的蛋白质二硫键异构酶及其应用
US11105747B2 (en) * 2017-03-20 2021-08-31 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105538C (en) * 1993-09-03 1999-03-09 Gregory Matlashewski Differentially expressed leishmania genes and proteins

Also Published As

Publication number Publication date
CN101274960A (zh) 2008-10-01
AU2002345672B2 (en) 2008-05-29
FR2826018B1 (fr) 2005-01-07
JP2004537299A (ja) 2004-12-16
WO2002103002A2 (fr) 2002-12-27
CN1526017A (zh) 2004-09-01
KR20040023621A (ko) 2004-03-18
HRP20031046A2 (en) 2004-04-30
MXPA03011904A (es) 2005-07-01
FR2826018A1 (fr) 2002-12-20
EP1414967A2 (fr) 2004-05-06
HUP0400204A3 (en) 2010-01-28
YU99603A (sh) 2006-05-25
AU2008203830A1 (en) 2008-09-11
PL367113A1 (en) 2005-02-21
WO2002103002A3 (fr) 2004-02-26
CZ20033430A3 (cs) 2004-05-12
JP2009254386A (ja) 2009-11-05
BR0210486A (pt) 2004-08-17
EP1414967B1 (fr) 2015-04-15
ZA200309739B (en) 2004-10-12
NZ530459A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
ES2545886T3 (es) Inmunoterapia dirigida a patógenos intracelulares
ATE411043T1 (de) Verfahren von dna-impfung
NO177678C (no) Fremgangsmåte for fremstilling av et terapeutisk aktivt, rekombinant protein som har ASP-aktivitet, ekspresjonssystem samt DNA som koder for nevnte protein
RU95115239A (ru) Аналог эритропоэтина
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
HUP0400669A2 (hu) Béta-amiloid analóg T-sejt vakcina
DE68919846T2 (de) Poxvirus-vektoren.
BR9907691A (pt) Derivados de antìgeno associado a tumor da famìlia mage, e sequências de ácido nucléico codificando os mesmos, usados para a preparação de proteìnas de fusão e de composições para vacinação
NO20045480L (no) Intergeniske regioner som innskuddsseter i genomet til vacciniavirus ankara(MVA)
HUP0302965A2 (hu) Vakcina
NO960309L (no) Agonister og antagonister for humaninterleukin-10
DE69840524D1 (de) Impfung durch topische verwendung genetischer vektoren
WO2023094713A3 (en) Coronavirus vaccine
Volpedo et al. The history of live attenuated centrin gene-deleted leishmania vaccine candidates
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
HUP0400204A2 (hu) A Leishmania parazita virulenciájával kapcsolatos gének
WO2023147092A3 (en) Coronavirus vaccine
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
Maharana et al. An overview on kinetoplastid paraflagellar rod
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
Prince et al. Tandem antioxidant enzymes confer synergistic protective responses in experimental filariasis
DE68923286T2 (de) Impfstoffe und testsätze für haemophilus influenzae.
CN103890004B (zh) 由具有特定免疫显性表位的婴儿利什曼虫pfr1蛋白片段组成的嵌合分子可用于抗利什曼病的免疫疗法
HUP0200302A2 (en) Malaria vaccine

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees